Floyd E. Romesberg

RQx Pharmaceuticals, Inc. operates as a biopharmaceutical company developing small molecule antibiotics. The firm develops small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. It is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. The company was founded in 2010 and is headquartered in La Jolla, CA.

Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.

Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA.